25I-NBOMe: Difference between revisions

Line 15:

==Pharmacology==

25I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT2A receptor]] where it acts as ~~a superpotent~~ [[Agonist#Agonists|partial agonist]].<ref name="pmid21174090">Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.

25I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT2A receptor]] where it acts as an unusually potent and selective [[Agonist#Agonists|partial agonist]].<ref name="pmid21174090">Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.

~~This~~ compound is pharmacologically unique ~~when compared to other psychedelics through its action on [[serotonin]] receptors. It is one~~ of the ~~only [[Agonist#Agonists|full agonists]] for~~ the ~~human [[Serotonin#The 5~~-~~HT system|5-HT2A~~ receptor~~]] receptor in existence~~.<ref name="pmid21174090" /> ~~In comparison~~, ~~classical psychedelics such as [[LSD]]~~, ~~[[DMT]] and [[psilocin]] can only be considered [[Agonist#Agonists|~~partial agonists]].

Among psychedelics, this compound is considered to be pharmacologically unique in terms of the high potency, affinity, and selectivity with which it binds to the 5HT-2a receptor.<ref name="pmid21174090" /> Contrary to popular belief, it is not a "full agonist", although questions have been raised about how the effects it produces differ from other 5HT-2a partial agonists, which include the range of traditional psychedelics.

The Ki values of the following targets were greater than 500 Ki: 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin reuptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine reuptake transporter.<ref name="high specific">High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/18468904</ref>

@@ Line 15: / Line 15: @@
 ==Pharmacology==
 {{Further|Serotonergic psychedelic}}
-I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a superpotent [[Agonist#Agonists|partial agonist]].<ref name="pmid21174090">Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
+I-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as an unusually potent and selective [[Agonist#Agonists|partial agonist]].<ref name="pmid21174090">Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
-This compound is pharmacologically unique when compared to other psychedelics through its action on [[serotonin]] receptors. It is one of the only [[Agonist#Agonists|full agonists]] for the human [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] receptor in existence.<ref name="pmid21174090" /> In comparison, classical psychedelics such as [[LSD]], [[DMT]] and [[psilocin]] can only be considered [[Agonist#Agonists|partial agonists]].
+Among psychedelics, this compound is considered to be pharmacologically unique in terms of the high potency, affinity, and selectivity with which it binds to the 5HT-2a receptor.<ref name="pmid21174090" /> Contrary to popular belief, it is not a "full agonist", although questions have been raised about how the effects it produces differ from other 5HT-2a partial agonists, which include the range of traditional psychedelics.
 The Ki values of the following targets were greater than 500 Ki: 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin reuptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine reuptake transporter.<ref name="high specific">High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/18468904</ref>